Britain's biggest drugmaker said on Monday that
Prosensa would now have full and unencumbered rights to drisapersen.
The move marks the termination of a 2009 collaboration agreement
between the two firms.
Hopes for the drug slumped last September when it did not show a
statistically significant improvement in the distance that patients
could walk in six minutes compared with a placebo in a final-stage
Phase III test run by GSK.
(Reporting by Ben Hirschler; editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.